Dermatotoxic effects of orally administered ciprofloxacin in sweating and nonsweating animal models

References

• Rafael de la T, Simona P. Usefulness of sweat testing for the detection of cannabis smoke. Clin Chem 2004; 50:1961–1962.
   PubMed Web of Science ®Google Scholar
• Muhammad F, Monteiro-Riviere NA, Baynes RE, Riviere JE. Effect of in vivo jet fuel exposure on subsequent in vitro dermal absorption of individual aromatic and aliphatic hydrocarbon fuel constituents. J Toxicol Environ Health A 2005; 68:719–737.
   PubMed Web of Science ®Google Scholar
• Stanley TO. Food and Nutrition Toxicology; Boca Raton, FL: CRC Press. 2004.
   Google Scholar
• Hoiby N, Jarlov JO, Kemp M, Tvede M, Bangsborg JM, Kjerulf A, et al. Excretion of ciprofloxacin in sweat and multiresistant Staphylococcus epidermidis. Lancet 1997; 18:167–169.
   Google Scholar
• Parnas J, Flachs H, Gram L, Wurtz-Jorgensen A. Excretion of antiepileptic drugs in sweat. Acta Neurol Scand 1978; 58:197–204.
   PubMed Web of Science ®Google Scholar
• Cone EJ, Hillsgrove MJ, Jenkins AJ, Keenan RM, Darwin WD. Sweat testing for heroin, cocaine, and metabolites. J Anal Toxicol 1994; 18:298–305.
   PubMed Web of Science ®Google Scholar
• Huestis MA, Scheidweiler KB, Saito T, Fortner N, Abraham T, Gustafson RA, et al. Excretion of delta 9-tetrahydrocannabinol in sweat. Forensic Sci Int 2008; 174:173–177.
   PubMed Web of Science ®Google Scholar
• Barnes AJ, Smith MI, Kacinko SL, Schwilke EW, Cone EJ, Moolchan ET, et al. Excretion of methamphetamine and amphetamine in human sweat following controlled oral methamphetamine administration. Clin Chemother 2008; 54(1):172–180.
   PubMed Web of Science ®Google Scholar
• Shah VP, Epstein WL, Riegelman S. Role of sweat in accumulation of orally administered griseofulvin in skin. J Clin Invest 1974; 53:1673–1678.
   PubMed Web of Science ®Google Scholar
• Dasgupta A. Handbook of Drug Monitoring Methods; Totowa, NJ: Humana Press Inc. 2008.
   Google Scholar
• Lee AB, John T. Drug-induced skin reactions. Pharm J 1999; 262:357–362.
   Google Scholar
• Robert C, Owens JR, Patel KB, Banevicius MA, Richard Q, Nightingale CH, et al. Oral bioavailability and pharmacokinetics of ciprofloxacin in patients with AIDS. Antimicrob Agents Chemother 1997; 41:1508–1511.
   PubMed Web of Science ®Google Scholar
• Javed I, Iqbal Z, Rahman ZU, Zargham MK, Muhammad F, Aslam B, et al. Disposition kinetics and optimal dosage of ciprofloxacin in healthy domestic ruminant species. Acta Vet Brno 2009; 78:155–162.
   Web of Science ®Google Scholar
• Weishar E, Diepgen TL, Bruckner T, Fartasch M, Kupfer J, LobCorzilius T, et al. Itch intensity evaluated in the German Atopic Dermatitis Intervention Study (GADIS): correlations with quality of life, coping behaviour and SCORAD severity in 823 children. Acta Derm Venereol 2008; 88:234–239.
   PubMed Web of Science ®Google Scholar
• Bidgood TL, Papich MG. Plasma and interstitial fluid pharmacokinetics of enrofloxacin, its metabolite ciprofloxacin, and marbofloxacin after administration and a constant rate intravenous infusion in dogs. J Vet Pharmacol Ther 2005; 28:329–341.
   PubMed Web of Science ®Google Scholar
• Barbara WK, William GR. Methods for skin absorption; Boca Raton, FL: CRC Press. 1990. 176–177.
   Google Scholar
• Monteiro-Riviere NA. Structure and function of skin. In: Riviere JE (ed.). Dermal Absorption Models in Toxicology and Pharmacology; Boca Raton, FL: CRC Press. 2006.1–19.
   Google Scholar
• Mandal B, Steward M, Singh S, Jones H. Ciprofloxacin-induced toxic epidermal necrolysis (TEN) in a nonagerian: a case report. Age Ageing 2004; 33:405–406.
   PubMed Web of Science ®Google Scholar
• Patrick JO, Arnold T, Capote LR. The Physiologic Basis of Surgery; 4th ed. London, UK: Lippincott Williams & Wilkins. 2007. 266–268.
   Google Scholar
• Macher E. Controversies in experimental dermatology. Exp Dermatol 2002; 11:174–175.
   Google Scholar
• Howard LJ, Maibach HI. Drug excretion in human eccrine sweat. J Invest Dermatol 1971; 56:182–188.
   PubMed Web of Science ®Google Scholar
• Frank GP, Lisanti MP. ICAM-1: role of inflammation and in the regulation of vascular permeability. Am J Physiol Heart Circ Physiol 2008; 295:926–927.
   PubMed Web of Science ®Google Scholar
• Fukuda S, Katsuo M, Takayuki K, Michiyo G, Yasuhiko K, Yasuko A, et al. Inhibition of allergic dermal inflammation by the novel imidazopyridazine derivative TAK-427 in a guinea pig experimental model of eczema. Am Soc Pharmacol Exp Ther 2002; 303:1283–1290.
   Web of Science ®Google Scholar
• Degreef H. Mechanisms in allergic disorders. J Eur Acad Dermatol Venereol 1997; 8:2–5.
   Google Scholar
• Kirkup ME, Narayan S, Kennedy CT. Cutaneous recall reactions with systemic fluorouracil. Dermatology 2003; 206:175–176.
   PubMed Web of Science ®Google Scholar
• Jacobi U, Waibler E, Schulze P, Sehouli J, Oskay-Ozcelik G, Schmook T, et al. Release of doxorubicin in sweat: first step to induce the palmar–plantar erythrodysesthesia syndrome. Ann Oncol 2005; 16:1210–1211.
   PubMed Web of Science ®Google Scholar
• Boelaert J, Valcke Y, Schurgers M, Daneels R, Rosseneu M, Rosseel MT, et al. The pharmacokinetics of ciprofloxacin in patients with impaired renal function. Br Soc Antimicrob Chemother 1985; 16:87–93.
   PubMed Web of Science ®Google Scholar
• Shayne CG. Animal Models in Toxicology; 2nd ed. Boca Raton, FL: CRC Press. 2007.
   Google Scholar
• Javed I, Nawaz M, Khan FH. Pharmacokinetic and optimal doses of kenamycin in domestic ruminant species. Veterinarski Arch 2003; 73:323–331.
   Google Scholar
• Alfredo Z, Raho E, Marconi B, Nicoli S, Santini M, Allegra F, et al. Plasma and skin concentration of 5-methoxypsoralen in psoriatic patients after oral administration. J Invest Dermatol 2001; 117:379–382.
   PubMed Web of Science ®Google Scholar